This is not the most recent version of the article. View current version (7 DEC 2011)

Intervention Review

Botulinum toxin injections for adults with overactive bladder syndrome

  1. James B Duthie1,*,
  2. G Peter Herbison2,
  3. David Iain Wilson3,
  4. Don Wilson4

Editorial Group: Cochrane Incontinence Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 21 MAY 2007

DOI: 10.1002/14651858.CD005493.pub2

How to Cite

Duthie JB, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD005493. DOI: 10.1002/14651858.CD005493.pub2.

Author Information

  1. 1

    Dunedin Public Hospital, Department of General Surgery, Dunedin, Otago, New Zealand

  2. 2

    Dunedin School of Medicine, University of Otago, Department of Preventive & Social Medicine, Dunedin, New Zealand

  3. 3

    Queen's Hospital, Emergency Department, Essex, UK

  4. 4

    Dunedin School of Medicine, University of Otago, Obstetrics & Gynaecology, Dunedin, New Zealand

*James B Duthie, Department of General Surgery, Dunedin Public Hospital, 104 Neidpath Road, Mornington, Dunedin, Otago, 9001, New Zealand. jbduthie@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

This is not the most recent version of the article.View current version (07 Dec 2011)

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary

Background

Overactive bladder syndrome is a common condition with a significant negative impact on quality of life. Intravesical injection of botulinum toxin is increasingly used as an intervention for refractory overactive bladder, with a considerable body of case reports and series in the literature suggesting beneficial effects.

Objectives

The objective was to compare intravesical botulinum toxin injection with other treatments for neurogenic and idiopathic overactive bladder in adults. The hypotheses addressed were whether intravesical injection of botulinum toxin was better: than placebo or no treatment, pharmacological and other non-pharmacological interventions, whether higher doses of botulinum toxin were better than lower doses, whether botulinum toxin in combination with other treatments was better than other treatments alone, whether one formulation of botulinum toxin is better than another, and whether one injection technique was better than another.

Search strategy

We searched the Cochrane Incontinence Group Specialised Trials Register (searched 22 November 2005). The register contains trials identified from MEDLINE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and handsearching of journals and conference proceedings. Additionally, all reference lists of selected trials were searched. No limitations were placed on the searches.

Selection criteria

All randomised or quasi-randomised controlled trials of treatment for overactive bladder syndrome in adults in which at least one management arm involved intravesical injection of botulinum toxin were included. Participants had either neurogenic or idiopathic overactive bladder with or without stress incontinence. Comparison interventions could include no intervention; placebo; lifestyle modification; bladder retraining; pharmacological treatments; surgery; bladder instillation techniques; neuromodulation; and different types, doses, and injection techniques of botulinum toxin.

Data collection and analysis

Binary outcomes were presented as relative risk and continuous outcomes by mean differences. No data could be synthesised across studies due to differing designs and outcome measures. Data were tabulated where possible with results taken from trial reports where this was not possible.

Where multiple publications were found, the reports were treated as a single source of data.

Main results

Eight studies met the inclusion criteria. Results varied between studies. For the most part, studies reported superiority of botulinum toxin A to placebo in such outcomes as incontinence episodes, bladder capacity, maximum detrusor pressure, and quality of life. Low doses of botulinum toxin (100U to150U) appeared to have beneficial effects, but higher doses (300U) may have been more effective. Botulinum toxin appeared to have beneficial effects in overactive bladder that quantitatively exceeded the effects of intravesical resiniferatoxin.

Authors' conclusions

Intravesical botulinum toxin shows promise as a therapy for overactive bladder symptoms, but as yet too little controlled trial data exist on benefits and safety compared with other interventions, or with placebo. Practitioners should be aware that at present there is little more than anecdotal evidence, in the form of case reports to support the efficacy of intravesical botulinum toxin; there is not much in the way of substantial, robust safety data. Furthermore, the optimal dose of botulinum toxin for efficacy and safety has not yet been demonstrated.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary

Botulinum toxin injections into the bladder for overactive bladder syndrome in adults

Injection of botulinum toxin into the bladder is being increasingly used to treat persistent overactive bladder syndrome. This is a disorder characterised by the sudden urge to pass urine, a frequent need to pass urine, and passing urine during the night, with or without incontinence. We explored the research relating to how effective and safe botulinum toxin injections into the bladder are, and what the best dose of botulinum toxin is. We found that there were very few comparative studies that involved a relatively small number of patients, but that there was some evidence that botulinum toxin can improve the symptoms of overactive bladder syndrome. It was unclear what the best dose of botulinum toxin was. Botulinum toxin injections into the bladder appeared to give few side effects or complications, but there were no long-term follow-up studies, and there could be rare side effects that have not been discovered yet.